Preserving the Promise: Improving the Culture of Biotech Investment
| Author | : | |
| Rating | : | 4.37 (826 Votes) |
| Asin | : | 0128092165 |
| Format Type | : | paperback |
| Number of Pages | : | 276 Pages |
| Publish Date | : | 2014-08-22 |
| Language | : | English |
DESCRIPTION:
He was an intern and resident at Brigham and Women’s Hospital and a Medical Oncology fellow at Dana Farber/Partners Cancer Care in Boston. Dr. Weinberg, an internationally renowned cancer researcher. He previously chaired the Life Sciences screening committee for Robin Hood Ventures and sits on the Life Science Investment Review committee for Ben Franklin Technology Partners. Fishman holds undergraduate
Five Stars V. Reinhardt Ordered for faculty at the University of Pennsylvania, no complaints. "Required reading for biotech entrepreneurs: bold, honest account of funding translational research" according to DocG. Dessain and Fishman have written a much needed and honest account of the challenges early stage biotechnology companies face when seeking funding. Developing high impact new drugs is difficult from many points of view. This book analyzes the challenges biotech entrepreneurs face in getting the first few dollars to move the science "from the bench" into clinical trials.Preserving the Promise is written by two experienced professionals - one is a doctor, professor, and biotech company
He has lectured on biotechnology innovation at the Wharton School of the University of Pennsylvania, the Harvard i-lab, and the Yale School of Management.Scott Fishman has more than three decades’ experience as a strategic advisor to the medical technology and pharmaceutical industries. He founded and was CEO of Research by Design (RBD), a healthcare consultancy he grew to one of the foremost names in the medical information industry. and Ph.D. He earned an undergraduate degree in biochemistry at Brown University and then M.D. . Robert A. He was a postdoctoral fellow at the Whitehead Institute for Biomedical Research in Cambridge, Massachusetts, working in the laboratory Dr.
It exposes the self-defeating habits of drug development in the Valley of Death, that waste money and extinguish innovative technologies through distorted financial incentives.Explains why translation of biotech discovery into medicine succeeds so infrequently that it’s been dubbed the Valley of DeathUncovers specific decision-making strategies that more effectively align incentives, improving clinical and financial outcomes for investors, inventor/entrepreneurs, and patientsExamines the critical, early stages of commercialization, where technology transfer offices and Angels act as gatekeepers to development, and where tension between short-term financial and long-term clinical aspirations sinks important technologiesDeconstructs the forces driving biotech, recasts them in a proven conceptual framework, and offers practical guidance for making the system better. Preserving the Promise: Improving the Culture of Biotech Investment critically examines wh